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Enterovirus 71 (EV71) causes childhood hand, foot, and mouth disease and neurological complications, and
no vaccines or therapeutic drugs are currently available. Formaldehyde-inactivated whole-virus vaccines
derived from EV71 clinical isolates and a mouse-adapted virus (MAV) were tested in a mouse model of EV71
encephalomyelitis. After only two immunizations, given to mice at 1 and 7 days of age, the MAV vaccine
protected mice at 14 days of age from disease. Tissues from immunized mice were negative for virus by viral
culture, reverse transcriptase PCR, immunohistochemistry analysis, and in situ hybridization. Cross-neutral-
izing EV71 antibodies to strains with genotypes B3, B4, and C1 to C5 generated in immunized adult mice were
able to passively protect 14-day-old mice from disease.
Enterovirus 71 (EV71), like poliovirus, is a nonenveloped,
single-stranded RNA virus that belongs to the genus Enterovi-
rus within the Picornaviridae family (22). Outbreaks of EV71-
associated hand, foot, and mouth diseases have been reported
worldwide, and hundreds of children have died from severe
complications of encephalomyelitis (1, 3, 4, 6, 8–10, 12, 13,
14–16, 18–20, 24).
There are currently no effective antiviral drugs available for
severe EV71 infection. The success of both formaldehyde-
inactivated and live-attenuated poliovirus vaccines in control-
ling poliovirus outbreaks highlights the potential control of
EV71 epidemics by mass vaccination.
Recently, several new formats of EV71 candidate vaccines
have been successfully developed. These included a DNA vac-
cine, an EV71-like particle vaccine, and a recombinant VP1
protein vaccine derived from milk samples from transgenic
mice engineered to produce VP1 capsid protein (5, 7, 28). All
of these vaccines are immunogenic and show good immune
responses in vaccinated mice (5, 7, 28). However, only the VP1
vaccine appears to show some direct evidence of protection in
that suckling mice feeding on milk that contained the vaccine
did not lose weight after virus challenge (5). However, the
efficacy of this vaccine was not evaluated by survival rate stud-
ies and pathological and virological analyses of immunized
animals.
Challenge studies following vaccination with the DNA and
EV71-like particle vaccines have not been reported, perhaps
because adult mice are not susceptible to clinical EV71 infec-
tion and so far only suckling mice of up to a week old are
susceptible to infection (26).
We recently described a new mouse model for EV71 en-
cephalomyelitis (21) that is similar to the human disease (27).
In this model, a genotype B3 clinical isolate (herein designated
13903; GenBank accession number AY207648) was serially
passaged five times to create a mouse-adapted virus (MAV)
that was able to infect mice up to 14 days old. In the present
study, this mouse model was used to test the protective efficacy
of formaldehyde-inactivated whole-virus vaccines. Following
immunization of mice at birth and administration of a booster
dose at day 7, we found complete protection from disease in
mice at day 14.
Vaccine preparation. Human EV71 strains 13903 (21),
A10/4 (genotype B4; GenBank accession number AF376067)
(2), and MAV (21), purified by limiting dilution, were grown in
Vero cells at a multiplicity of infection of 5 at 36°C in Dulbec-
co’s modified Eagle’s medium without fetal bovine serum. The
infected culture was kept until all cells showed a cytopathic
effect. The culture was subjected to three freeze-thaw cycles
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TABLE 1. Clinical isolates of EV71 strains used in this study
Isolate
no. Virus strain Genotype Origin Year Reference
1 13903 B3 Malaysia 1997 21
2 MF B3 Malaysia 1997 11
3 MY104-9 B3 Malaysia 1998 2
4 CS B4 Malaysia 1997 11
5 A10/4 B4 Malaysia 2000 2
6 9522 C1 Malaysia 2003 23
7 8 M/6/99 C2 Australia 1999 2
8 001-KOR-00 C3 Korea 2000 2
9 VN5559 C4 Vietnam 2005 25
10 VN5784 C5 Vietnam 2005 25
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and clarified by centrifugation at 4,500 rpm for 10 min at 4°C.
The supernatant was filtered through a 0.2-m-pore-size filter
(Sartorius, Germany). The virus titer was determined using the
50% cell culture infective dose (CCID50) assay with Vero cells
as described previously (21). Prior to formaldehyde inactiva-
tion, the virus suspension was again filtered as described above
to remove any viral aggregates in order to facilitate formalde-
hyde penetration into all virus particles. Inactivation was car-
ried out by adding 37% formaldehyde (Merck, Denmark) to
the virus suspension to give a final formaldehyde dilution of
1/4,000 and incubating the suspension for 14 days at 37°C (17).
The inactivated virus suspension was filtered again as de-
scribed above and stored at 80°C. In this way, three inacti-
vated-virus vaccines, the 13903, A10/4, and MAV vaccines,
were prepared. No live viruses were detected after repeated
Vero cell cultures for a period of up to 3 weeks. The protein
concentrations in inactivated virus preparations were deter-
mined using the Coomassie Plus (Bradford) assay kit according
to the procedures of the manufacturer (Pierce).
Immunogenicities of inactivated-virus vaccines in adult
mice. Three groups (n  6 per group) of 4- to 6-week-old ICR
mice were each immunized via the intraperitoneal (i.p.) route
with one of the three inactivated whole-virus vaccines in a dose
of 0.25 ml (20 g) containing 0.5 mg/ml aluminum hydroxide
(Sigma). The immunization schedule consisted of two inocu-
lations given 1 week apart. The mice were sacrificed at day 14
postimmunization, and sera were tested for neutralizing anti-
bodies against several EV71 clinical isolates (isolates 1 to 5)
(Table 1) by the microneutralization test as described previ-
ously (28). Briefly, serial twofold dilutions of serum samples
were mixed with 100 CCID50 of virus, and the neutralization
antibody titer was the highest dilution of serum that protected
50% of the cultures. Our preliminary data indicated that the
MAV vaccine induced the highest neutralizing antibody titers
and, hence, was likely to have greater potential to be effective
against genotype B viruses than the other two vaccines (Table
2). Hence, further testing with the MAV-induced antibodies
was performed with clinical isolates of genotypes C1 to C5
(isolates 6 to 10) (Table 1). Antisera generated by immuniza-
tion with the MAV vaccine not only neutralized genotype B3
EV71 strains, but also neutralized strains of genotypes B4 and
C1 to C5, with the highest neutralizing activity against geno-
types B3 and B4 and the lowest activity against genotype C4
(Table 2).
Active immunization of and challenge experiments with
suckling mice. (i) Survival rates. Since the MAV vaccine
showed the highest neutralizing antibody titers, it was used for
further vaccination experiments; the other two vaccines were
not studied further. All animal experiments were performed
after obtaining ethical clearance and in accordance with insti-
tutional (University of Malaya) guidelines on animal welfare
and the use of laboratory animals.
FIG. 1. Survival graph for mice (immunized and unimmunized) after i.p. challenge with lethal doses of mouse-adapted EV71.




Titer of antibodiesa against:
13903 MF MY104-9 CS A10/4 9522 8 M/6/99 001-KOR-00 VN5559 VN5784
MAV 1/512 1/512 1/512 1/512 1/512 1/256 1/64 1/256 1/32 1/64
A10/4 1/32 1/32 1/32 1/32 1/32 ND ND ND ND ND
13903 1/64 1/32 1/32 1/32 1/32 ND ND ND ND ND
Control 1/8 1/8 1/8 1/8 1/8 1/8 1/8 1/8 1/8 1/8
a Virus strains were tested in microneutralizing assays. ND, not determined.
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FIG. 2. Pathological findings for immunized and unimmunized mice after i.p. challenge with lethal doses of mouse-adapted EV71. (A to C) An
unimmunized mouse exhibited hind limb (arrow) and front limb (arrowhead) paralysis at 3 dpi (A). No significant lesions in the skeletal muscle
from an immunized mouse were observed (B); in contrast, severe necrosis with mild inflammatory cell infiltration was observed in muscle from
the unimmunized mouse (C). (D to K) In the brain stem of the immunized mouse, no viral antigens (D) or RNA (F) were detected. Similarly, no
viral antigens (H) and RNA (J) were detected in skeletal muscle fibers. In the unimmunized mouse, numerous brain stem neurons were positive
for viral antigens (E, arrows) and RNA (G, arrows). Skeletal muscle fibers were also positive for viral antigens (I, arrows) and RNA (K, arrows).
Samples in panels B and C were stained with hematoxylin and eosin stain; samples in panels D, E, H, and I were subjected to IHC analysis with
DAB (3,3-diaminobenzidine) chromogen and hematoxylin counterstain; samples in panels F, G, J, and K were analyzed by ISH with Nitro Blue
Tetrazolium-BCIP (5-bromo-4-chloro-3-indolylphosphate) substrate and hematoxylin counterstain. Original magnifications, 20 (B to K).
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The MAV vaccine was tested with 1-day-old ICR mice (n 
8) by the subcutaneous route using 0.05 ml (4 g) of vaccine
containing 0.5 mg/ml aluminum hydroxide. Eight additional
mice served as negative controls and received only normal
saline injections. Mice were boosted at day 7 and challenged by
the i.p. route with 50 50% lethal doses (LD50) of live MAV at
day 14. The mice were then monitored for paralysis or death
for the next 14 days. The survival graph for immunized and
unimmunized animals after live-virus challenge is shown in Fig.
1. The MAV vaccine protected 100% of immunized mice from
weight loss, paralysis, and death. The protection level was only
50% when no booster was given (results not shown). All un-
immunized animals developed signs of acute disease charac-
terized by progressive hind or front limb paralysis (Fig. 2A)
and weight loss at 3 days postinfection (dpi) and death at 4 to
7 dpi.
(ii) Histopathology, virus titer determination, and virus de-
tection. Histopathological changes, virus titers, and viral anti-
gens/RNA in tissues from two further sets of nine immunized
and nine unimmunized suckling mice after virus challenge
were studied. However, all mice were sacrificed at 4 dpi. Three
mice from each group were used for (i) histopathology analy-
sis, (ii) virus titer determination, and (iii) reverse transcriptase
PCR (RT-PCR). For histopathology analysis, the whole mouse
was fixed in 10% buffered formalin for 5 days. Seven standard
whole-body, cross-sectional, paraffinized tissue blocks were
prepared. Tissue sections were stained with hematoxylin and
eosin, and immunohistochemistry (IHC) and in situ hybridiza-
tion (ISH) analyses were performed as described previously
(21). In unimmunized mice, limb skeletal muscles revealed
extensive, severe necrotizing myositis (Fig. 2C). Viral antigens
(Fig. 2E) and viral RNA (Fig. 2G) were detected in neurons of
the central nervous system (CNS). Viral antigens (Fig. 2I) and
RNA (Fig. 2K) were diffusely observed within the skeletal
muscle fibers. In contrast, no significant pathology was ob-
served in the muscles (Fig. 2B, H, and J) and CNS tissues (Fig.
2D and F) of immunized mice.
For virus titer determination, hind limb muscles, lower and
upper spinal cords, and brain stems were weighed and homog-
enized in phosphate-buffered saline to 10% (wt/vol). Virus
titers were determined as described above. Virus titers in tis-
sues were expressed as the mean log10 CCID50  the standard
error of the mean for pooled 10% tissue homogenates from
groups of three mice at 4 dpi. Virus titers in sera were ex-
pressed as the log 10 CCID50 per milliliter. In general, all
unimmunized mice showed evidence of virus in sera, hind limb
muscles, and CNS tissues, whereas no virus was ever isolated
from brain stems, upper and lower spinal cords, hind limbs, or
sera from immunized mice (Fig. 3).
Total RNA was extracted from homogenized hind limb mus-
cles, upper and lower spinal cords, brain stems, and sera by
using Trizol reagent according to the procedure of the manu-
facturer (Invitrogen). RT-PCR with gene-specific primers (27)
and beta-actin primers as an internal control was then per-
formed using the Titan One-Tube RT-PCR system according
to the procedures of the manufacturer (Roche, Germany).
Similar to virus titer, IHC, and ISH analyses, the RT-PCR was
negative for tissues from all the immunized mice but positive
for the unimmunized group.
Passive immunization of and challenge experiments with
suckling mice. To confirm the importance of the humoral
immune response in protection, undiluted, heat-inactivated,
pooled sera from previously immunized adult mice were given
to a group of 14-day-old ICR mice (n  8) while a control
group (n  8) received normal sera from naïve mice. Mice
were given 0.2 ml of sera with neutralizing antibody titers of
1/512 or normal sera by the i.p. route. One hour later, the
animals were challenged with 10 LD50 of live MAV, and they
received a second injection of 0.2 ml of sera 24 h later. The
mice were observed for signs of disease for 7 days. All mice
FIG. 3. Virus titers in brain stems, upper and lower spinal cords, hind limb muscles, and sera from immunized and unimmunized mice
challenged with lethal doses of mouse-adapted EV71 by the i.p. route.
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that received the hyperimmune sera were completely pro-
tected, with no signs of disease whatsoever. In contrast, all
mice that received the naïve sera developed paralysis or died
within 4 to 5 dpi.
In summary, suckling mice immunized with the adjuvant-
carrying formaldehyde-inactivated MAV vaccine at 1 and 7
days of age were effectively protected from lethal virus chal-
lenge and disease at 14 days. The results of this study further
suggest that protection against disease as indicated by the
absence of weight loss, paralysis, death, and virus in sera and
CNS and skeletal muscle tissues correlates with the presence of
neutralizing antibodies. In this mouse model, viral replication
in skeletal muscles appears to precede viral spread to the CNS,
and indeed, retrograde peripheral motor nerve transmission
was thought to be responsible (21). We believe that the inhi-
bition of viremia by neutralizing antibodies induced by vac-
cines prevented skeletal muscle and CNS infection in the
mouse model. However, further studies are needed to deter-
mine the possible roles of cellular immunity in protection.
Genomic comparison between EV71 strains 13903 and
MAV revealed several nucleotide differences, including two
each in the VP2 and VP1 structural genes (unpublished data).
However, analysis of deduced amino acid sequences showed
that MAV had only one amino acid substitution each in the
VP2 and VP1 regions that is different from the sequence in the
13903 strain. Whether or not these differences acting alone or
in combination with other unknown factors cause increased
immunogenicity of the MAV vaccine needs to be further in-
vestigated.
This formaldehyde-inactivated MAV vaccine could serve as
a useful prototype vaccine, as it appears to be highly effective
against EV71 infection in our mouse model. Similar ap-
proaches may be applied for the development of vaccines
against EV71 infection in humans.
We are deeply indebted to Hiroyuki Shimizu for providing us with
the EV71 antiserum.
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